Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral treatments for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin, targets type 1 diabetes by improving glycemic control and reducing hypoglycemia risk. The company focuses on innovative mechanisms, strategic collaborations, and international trials to bring first-in-class therapies to market, addressing significant unmet medical needs in diabetes and chronic inflammatory conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.